Caris Life Sciences, Inc.
CAI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $216,833 | $181,398 | $120,915 | $100,049 |
| % Growth | 19.5% | 50% | 20.9% | – |
| Cost of Goods Sold | $69,327 | $67,713 | $63,852 | $62,495 |
| Gross Profit | $147,506 | $113,685 | $57,063 | $37,554 |
| % Margin | 68% | 62.7% | 47.2% | 37.5% |
| R&D Expenses | $21,624 | $25,047 | $23,066 | $24,787 |
| G&A Expenses | $51,973 | $64,367 | $53,362 | $41,068 |
| SG&A Expenses | $93,240 | $106,627 | $91,948 | $79,778 |
| Sales & Mktg Exp. | $41,267 | $42,260 | $38,586 | $38,710 |
| Other Operating Expenses | $0 | -$35,978 | $1 | -$134,022 |
| Operating Expenses | $114,864 | $95,696 | $115,015 | -$29,457 |
| Operating Income | $32,642 | $17,989 | -$57,952 | $67,011 |
| % Margin | 15.1% | 9.9% | -47.9% | 67% |
| Other Income/Exp. Net | -$8,317 | -$89,779 | -$44,629 | -$133,197 |
| Pre-Tax Income | $24,325 | -$71,790 | -$102,581 | -$66,186 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $24,325 | -$71,790 | -$102,581 | -$66,186 |
| % Margin | 11.2% | -39.6% | -84.8% | -66.2% |
| EPS | 0.086 | -1.93 | -0.4 | -0.35 |
| % Growth | 104.5% | -382.5% | -14.3% | – |
| EPS Diluted | 0.082 | -1.87 | -0.4 | -0.35 |
| Weighted Avg Shares Out | 282,099 | 268,444 | 254,789 | 254,789 |
| Weighted Avg Shares Out Dil | 297,212 | 276,000 | 254,789 | 254,789 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,360 | $1,618 | $503 | $2,640 |
| Interest Expense | $13,507 | $19,208 | $12,782 | $13,674 |
| Depreciation & Amortization | $4,870 | $6,409 | $7,045 | $11,610 |
| EBITDA | $42,702 | -$46,173 | -$82,754 | -$40,902 |
| % Margin | 19.7% | -25.5% | -68.4% | -40.9% |